2nd Next Generation Kinase Inhibitors Summit
Evvnt Promotion / evvnt
22.02.2023 - 23.02.2023 Boston Park Plaza, 50 Park Plaza, 02116 Boston, USA
Time: 8:00 am to 6:00 pm
Kongressthemen
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
Wissenschaftliche Fach-Gesellschaft
Hanson Wade
Hanson Wade
Anmerkungen
Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences
Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences
Anfragen und Anmeldung:
https://go.evvnt.com/1446853-3?pid=4832
Herr Min Ratcliffe
Gesundheitsversorgung, Public Health
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
